Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Systematic review of amifostine for the management of oral mucositis in cancer patients|
|Citation:||Supportive Care in Cancer, 2013; 21(1):357-364|
|Ourania Nicolatou-Galitis, Triantafyllia Sarri, Joanne Bowen, Mario Di Palma, Vassilios E. Kouloulias, Pasquale Niscola, Dorothea Riesenbeck, Monique Stokman, Wim Tissing, Eric Yeoh, Sharon Elad, Rajesh V. Lalla|
|Abstract:||PURPOSE The aim of this study was to review the available literature from 1966 until December 31, 2010 and define clinical practice guidelines for the use of amifostine for the prevention and treatment of oral mucositis in cancer patients. METHODS A systematic review was conducted by the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology. The body of evidence for the use of amifostine, in each cancer treatment setting was assigned an evidence level. Based on the evidence level, one of the following three guideline determinations was possible: recommendation, suggestion, or no guideline possible. RESULTS Thirty papers were reviewed for evidence on amifostine as an intervention for oral mucositis. No guideline was possible for amifostine in any cancer treatment setting due to inadequate and conflicting evidence. CONCLUSION Review of the amifostine studies for the prevention and treatment of oral mucositis has found insufficient evidence to support its use in any cancer treatment setting for this purpose. Additional well-designed research is needed to clarify the role of amifostine as an intervention for oral mucositis.|
|Keywords:||Amifostine, Guidelines, Systematic review, Oral mucositis|
|Rights:||© Springer-Verlag Berlin Heidelberg 2012|
|Appears in Collections:||Medical Sciences publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.